Hits from an in silico derived focused library for CRTH2 were transformed into highly selective antagonists with favorable ADME properties. Oral administration of 4-bromo-2-(1-phenyl-1H-pyrazole-4-carbonyl)phenoxyacetic acid (19) inhibited peribronchial eosinophilia and mucus cell hyperplasia in a mouse model of allergic asthma, supporting the therapeutic potential of this novel compound class. In addition, this selective pharmacological tool compound provides further evidence for CRTH2 as a relevant therapeutic target for treatment of Th2- and eosinophil-related inflammation.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1021/jm060657g | DOI Listing |
Publication Analysis
Top Keywords
silico derived
8
novel selective
4
selective orally
4
orally active
4
active crth2
4
crth2 antagonists
4
antagonists allergic
4
allergic inflammation
4
inflammation developed
4
developed silico
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!